Opportunities for Non-Hormonal Treatment of Breast Benign Dysplasia

Authors

  • Orazov M.R Peoples' Friendship University of Russia, 117198, Moscow, Miklukho-Maklaya str., 6 Author
  • Nosenko E.N Odessa National Medical University, Ministry of Health of Ukraine, 65082, Ukraine, Odessa, Valikhovsky, 2 Author
  • Pokul L.V Federal State Budgetary Institution of Healthcare “Novorossiysk Clinical Center of the Federal Biomedical Agency”, 353900, Novorossiysk, ul. Novorossiysk Republic Author
  • Toktar L.R Peoples' Friendship University of Russia, 117198, Moscow, Miklukho-Maklaya str., 6 Author
  • Sakultsan O.S State Budgetary Healthcare Institution "Oncology Dispensary No. 3" of the Ministry of Health of the Krasnodar Region, 353915, Russia, Krasnodar Region, Novorossiysk, Lieutenant Schmidt str., 7. Author
  • Rutinskaya A.V Medical Center for Reproductive Health "Gameta", 65000, Ukraine, Odessa, st.Slepneva, d.3A. Author
  • Akhmatova A.N Peoples' Friendship University of Russia, 117198, Moscow, Miklukho-Maklaya str., 6 Author

DOI:

https://doi.org/10.61841/ypzfrt42

Keywords:

Estrogens Stimulate, Algological Analysis, Prospective, Double-Blind, Placebo-Controlled Study

Abstract

Benign breast dysplasia (BBD) is widespread in the female population and is one of the most important risk factors for breast cancer. The use of ultra-diluted natural products in the treatment of diseases and in the treatment of hyper proliferative processes and cancer causes great interest and controversies. The aim of the study was to investigate the effectiveness and safety of the non-hormonal drug Mastopol® in the treatment of various forms of BBD in women of reproductive age. 

Downloads

Download data is not yet available.

References

1. Adamyan LV, Andreeva EN, Artymuk NV, Belokrinitskaya TE, Korzhenkova GP, Protasova AE, etc. Benign breast dysplasia. Clinical recommendations (treatment protocol). Ministry of Health of the Russian Federation. Moscow, 2018: 48 p.

2. Byvaltsev VA, White EG, Alekseev NV, Sorokovikov VA. The use of scales and questionnaires in the examination of patients with degenerative lesions of the lumbar spine: guidelines. Irkutsk: FSBI "NTSRVH" SB RAMS, 2013: 32 p.

3. Zotov AC, Belik EO. Mastopathy and breast cancer. M: MEDpressinform, 2005: 112 p.

4. Ledina AB, Prilepskaya VN. Mastalgia: clinics, diagnosis, treatment. Gynecology. 2011; 5: 66-76.

5. Mammology: national leadership. Ed. KaprinaAD, Rozhkova NI. 2nd ed., Revised. and add. M: GEOTAR Media, 2016: 496 p.

6. Matveeva EV. Asymmetry, blood flow and calcium fluoride - a view of the diagnostician on the reproductive sphere. Effective pharmacotherapy. Obstetrics and gynecology. 2016; 5: 20-26.

7. Muravyova DA, Samylina IA, Yakovlev GP, Pharmacognosy: Textbook. 4th ed., Rev. and add. M: Medicine. 2002: 656 p.

8. Pokul LV, Chugunova ON. Oxidative stress in the genesis of benign breast dysplasia and the possibility of its correction. Gynecological endocrinology. 2016; 3 (120): 18-24.

9. Radzinsky VE, Ordian IM,Maslennikov MN, Pavlova EA. Breast and gynecological diseases: from a community of pathogenetic views to practical solutions. Reproductive endocrinology. 2014; 2 (16): 72-78.

10. Sotnikova LS, Golubyatnikova EB. To the question of the effectiveness of treatment of benign breast pathology. Effective pharmacotherapy. 2016; 31: 6-12.

11. Sukhanova AA, Miller YuM, Karlova OO. Modern approaches to the treatment of mastopathy in patients of reproductive age. Women's health. 2016; 5 (111): 101-108.

12. Seagull VK, Lasachka SA, Gukova DU, Uman EU. Diagnosis, treatment and prevention of breast diseases in the context of reforming the healthcare system in Ukraine. Medical aspects of women's health. 2013; 1 (64): 5–9.

13. Chistyakov SS. Fibrocystic disease and breast benign tumors. Clinical mammology. The current state of the problem. Ed. EB Kampova-Field, SS Chistyakova. M: GEOTAR Media, 2006: 116–143.

14. Aceves C, Anguiano B, Delgado G. Is iodine a gatekeeper of the integrity of the mammary gland? J Mammary

Gland Biol Neoplasia. 2005; 10: 189–196.

15. Ayati SH, Fazeli B, Momtazi-Borojeni AA, Cicero AFG, Pirro M, Sahebkar A. Regulatory effects of berberine

on microRNome in Cancer and other conditions. Crit Rev Oncol Hematol. 2017 Aug; 116: 147-158. doi:

10.1016 / j.critrevonc. 2017.05.008.

16. Bell IR, Sarter B, Standish LJ, Banerji P, Banerji P. Low Doses of Traditional Nanophytomedicines for Clinical

Treatment: Manufacturing Processes and Nonlinear Response Patterns. J NanosciNanotechnol. 2015 Jun; 15

(6): 4021-38.

17. Biswas R., Mandal SK, Dutta S, Bhattacharyya SS, Boujedaini N, Khuda-Bukhsh AR. Thujone-rich fraction of

Thujaoccidentalis demonstrates major anti-cancer potentials: evidences from in vitro studies on A375 cells.

Evid Based Complement Alternat Med. 2011; 2011: 568148. doi: 10.1093 / ecam / neq042.

18. Breast cancer risk assessment and screening an average-risk women. Practice Bulletin No. 179. American

College of Obstetricians and Gynecologists. Obstet Gynecol. 2017; 130: 1-16.

19. Chang LC, Song LL, Park EJ. Bioactive constituents of Thujaoccidentalis. J Nat Prod. 2000; 63 (9): 1235–1238.

20. Effects of Mastalgia in Young Women on Quality of Life, Depression, and Anxiety Levels. Indian J Surg. 2016

Apr; 78 (2): 96-9. doi: 10.1007 / s12262-015-1325-5.

21. Frenkel M, Mishra BM, Sen S, Yang P, Pawlus A, Vence L, et al. Cytotoxic effects of ultra-diluted remedies on

breast cancer cells. Int J Oncol. 2010 Feb; 36 (2): 395-403.

22. Kataria K, Dhar A, Srivastava A, Kumar S, Goyal A. A systematic review of current understanding and

management of mastalgia. Indian J Surg. 2014; 76; 3: 217–222. doi: 10.1007 / s12262-013-0813-8.

23. Mansel RE, Das T, Baggs GE, Noss MJ, Jennings WP, Cohen J, et al. A Randomized Controlled Multicenter

Trial of an Investigational Liquid Nutritional Formula in Women with Cyclic Breast Pain Associated with

Fibrocystic Breast Changes. J Womens Health (Larchmt). 2018; 27 (3): 333-340. doi: 10.1089 / jwh.2017.6406.

24. Mansel RE, Webster DJT, Sweetland HM. Breast pain and nodularity. Chapt. 8. Benign disorders and disease of

the breast. 3rd ed. Saunders Elsevier, Philadelphia, 2009: 107–138.

25. McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Cocco L, Ratti S, et al. Regulation of GSK-3

activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. Adv Biol Regul. 2017

Aug; 65: 77-88. doi: 10.1016 / j.jbior.2017.05.05.005.

26. Naser B, Bodinet C, Tegtmeier M, Lindequist U. Thujaoccidentalis (Arbor vitae): a review of its

pharmaceutical, pharmacological and clinical properties. Evid Based Complement Alternat Med. 2005; 2 (1):

69–78

Downloads

Published

30.04.2020

Issue

Vol. 24 No. 2 (2020): 24 (2) 2020

Section

Articles

License

Copyright (c) 2020 AUTHOR

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

M.R, O., E.N, N., L.V, P., L.R, T., O.S, S., A.V, R., & A.N, A. (2020). Opportunities for Non-Hormonal Treatment of Breast Benign Dysplasia. International Journal of Psychosocial Rehabilitation, 24(2), 690-705. https://doi.org/10.61841/ypzfrt42